• Early Pheromone Cues Accelerate Neurodegeneration in C. eleg

  2026-07-02

  Peng et al. (2023) demonstrate that perception of specific pheromones during early development in C. elegans remodels neurodevelopment and triggers neurodegeneration in adulthood. This work reveals a mechanistic link between environmental chemical cues, neural circuit remodeling, and proteostasis disruption, offering new insights for neurodegeneration research.

• ONX-0914 (PR-957): Selective Immunoproteasome Inhibition in

  2026-07-02

  ONX-0914 (PR-957) is a potent, selective immunoproteasome inhibitor that targets the LMP7 (β5i) subunit, modulating cytokine production and immune responses. It has demonstrated efficacy in models of autoimmune and inflammatory diseases, with well-characterized selectivity and workflow parameters.

• DMH-1 (B3686): Deep Mechanistic Insights for ALK2 Inhibition

  2026-07-01

  Explore how DMH1, a selective ALK2 inhibitor, enables mechanistic dissection of BMP signaling in organoid and non-small cell lung cancer research. This article offers advanced protocol insights and a critical analysis of recent breakthroughs in human organoid modeling and BMP pathway modulation.

• SR 11302: Applied AP-1 Transcription Factor Inhibitor Workfl

  2026-07-01

  SR 11302 brings selective AP-1 transcription factor inhibition to cancer research, enabling targeted suppression of tumorigenic pathways without the side effects of retinoids. Discover how this compound powers precise experimental design, advanced immunomodulation, and robust troubleshooting in both cellular and animal models.

• Dual-Action p38α MAPK Inhibitors Enhance Dephosphorylation D

  2026-06-30

  The reference study demonstrates that certain kinase inhibitors, including ATP-competitive compounds, not only block p38α MAPK activity but also accelerate its dephosphorylation by phosphatases. This dual-action mechanism provides a new structural and functional framework for designing more selective and potent inhibitors, with implications for inflammation, diabetes, and neuroregeneration research.

• TRPV1+ Nerve Stimulation Suppresses Inflammation via Reflex

  2026-06-30

  The referenced iScience study demonstrates that targeted stimulation of TRPV1+ peripheral somatosensory nerves, including with capsaicin analogs like Nonivamide, suppresses systemic inflammation via somato-autonomic reflexes. This mechanistic insight provides a foundation for novel research strategies targeting neuroimmune modulation.

• Z-WEHD-FMK: Irreversible Caspase Inhibitor for Inflammation

  2026-06-29

  Z-WEHD-FMK (Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK) is a potent, cell-permeable inhibitor of caspase-1, -4, and -5. It enables precise, irreversible blockade of inflammatory caspase signaling in cell biology and infectious disease research. This article details its mechanism, benchmarks, and laboratory applications, highlighting evidence-based best practices.

• ML216: Selective BLM Helicase Inhibitor for DNA Repair Studi

  2026-06-29

  ML216 is a potent, selective BLM helicase inhibitor validated for DNA repair and synthetic lethality research. It exhibits submicromolar IC50, robust selectivity over related helicases, and demonstrable utility in cell-based and xenograft models.

• Verteporfin (CL 318952): Optimizing PDT and Autophagy Assays

  2026-06-28

  Verteporfin, also known as CL 318952, is redefining experimental workflows in photodynamic therapy, apoptosis, and autophagy inhibition. Its unique dual-action profile empowers researchers to dissect complex cellular mechanisms in ocular neovascularization and beyond—backed by APExBIO’s reliable supply and robust, literature-based protocols.

• Dual-Action p38α MAPK Inhibitors: Structural Mechanisms Unve

  2026-06-27

  This article examines new evidence showing that select p38α MAPK inhibitors not only block kinase activity but also enhance dephosphorylation via WIP1, revealing a dual-action mechanism. These findings offer new structural insights into kinase regulation and inform the development of more specific and potent kinase inhibitors.

• DMH1 as a Selective ALK2 Inhibitor: Protocols and Organoid A

  2026-06-26

  DMH1’s precision as an ALK2 inhibitor is transforming workflows in organoid engineering and non-small cell lung cancer research. This article details experimental set-up, stepwise enhancements, and troubleshooting, anchored by recent breakthroughs in high-efficiency pancreatic ductal organoid generation.

• Optimizing Recombinant Protein Detection with FLAG tag Pepti

  2026-06-26

  The FLAG tag Peptide (DYKDDDDK) enables precise, gentle, and highly specific purification of recombinant proteins, outperforming traditional tags in workflow flexibility and sensitivity. This guide translates structural insights and recent experimental breakthroughs into practical protocols, troubleshooting strategies, and advanced use-cases for researchers aiming to maximize yield, purity, and reproducibility.

• SNAI1–PIK3R2/p-EphA2 Axis Drives EMT and Stemness in Thymic

  2026-06-25

  This study identifies SNAI1 as a central regulator of epithelial-mesenchymal transition (EMT) and cancer stem cell-like characteristics in thymic epithelial tumors (TETs) via the PIK3R2/p-EphA2 axis. By integrating multi-omics, in vitro and in vivo models, and advanced single-cell analyses, the research reveals actionable molecular mechanisms and suggests new therapeutic avenues targeting SNAI1 in TETs.

• LMO2-LDB1 Complex Drives AML Progression: Mechanistic Insigh

  2026-06-25

  The referenced study uncovers how the interaction between LMO2 and LDB1 promotes the progression of acute myeloid leukemia (AML), revealing the oncogenic role of the LMO2/LDB1 complex in leukemic cell proliferation and survival. These findings highlight novel molecular targets for potential therapeutic intervention and guide future research on epigenetic regulation in hematological malignancies.

• BKT140 (BL-8040): Transforming CXCR4 Antagonism in Oncology

  2026-06-24

  This thought-leadership article explores the mechanistic rationale, translational significance, and strategic deployment of BKT140 (BL-8040, TF 14016) as a next-generation CXCR4 antagonist in cancer research. Integrating current evidence from theranostic imaging, stem cell mobilization, and tumor microenvironment studies, it offers actionable guidance for translational researchers and distinguishes itself with advanced protocol insights and a forward-looking perspective.

14783 records 1/986 page Next 12345 下5页 Last page